- Open
- 1966.00
- High
- 1982.00
- Low
- 1868.00
- Close
- 1918.00
- Change
- -38.50 (-1.97%)
- Volume
- 9,408,320
| 17 Jul 2026 | 12:00:01 | Audit tender conclusion |
| 17 Jul 2026 | 09:30:00 | Camlipixant phase III results update |
| 16 Jul 2026 | 15:30:00 | Director/PDMR Shareholding |
| 15 Jul 2026 | 13:38:08 | GSK completes acquisition of Nuvalent, Inc |
| 5 Mar 2026 | 2025 Annual Financial Report | |
| 27 Feb 2025 | 2024 Annual Financial Report | |
| 1 Mar 2024 | 2023 Annual Financial Report |
GSK plc, previously known as GlaxoSmithKline plc, is a multinational biotechnology and pharmaceutical corporation based in London, England, with a worldwide presence.
| 17 Jul 2026 | 12:00:01 | Audit tender conclusion |
| 17 Jul 2026 | 09:30:00 | Camlipixant phase III results update |
| 16 Jul 2026 | 15:30:00 | Director/PDMR Shareholding |
| 15 Jul 2026 | 13:38:08 | GSK completes acquisition of Nuvalent, Inc |
| 5 Mar 2026 | 2025 Annual Financial Report | |
| 27 Feb 2025 | 2024 Annual Financial Report | |
| 1 Mar 2024 | 2023 Annual Financial Report |
GSK plc, previously known as GlaxoSmithKline plc, is a multinational biotechnology and pharmaceutical corporation based in London, England, with a worldwide presence.
| 14 Jul 2026 |
| 15:30:01 |
| Director/PDMR Shareholding |
| 4 Jun 2026 |
| US bank sees GSK oncology pipeline as major value driver after New York conference |
Lord Balfe has interests in this issuer
| 14 Jul 2026 |
| 15:30:01 |
| Director/PDMR Shareholding |
| 4 Jun 2026 |
| US bank sees GSK oncology pipeline as major value driver after New York conference |
Lord Balfe has interests in this issuer
